AP NEWS

Cardiac Pacemakers - Global Market Trends & Opportunities to 2023: Analysis by Type (Implantable & External) and Geography - ResearchAndMarkets.com

September 26, 2018

DUBLIN--(BUSINESS WIRE)--Sep 26, 2018--The “Global Cardiac Pacemakers Market - Segmented by Type (Implantable and External), and Geography - Growth, Trends, and Forecast (2018 - 2023)” report has been added to ResearchAndMarkets.com’s offering.

The cardiac pacemakers market is expected to register a CAGR of 6.8% over the forecast period.

The increasing prevalence of heart diseases and ageing population are driving the market. According to Centers for Disease Control and Prevention (CDC) statistics, more than three million people in the United States suffer from atrial fibrillation, which is the most common type of abnormal heart rhythm, and the number is expected to quadruple by 2050.

Arrhythmias affects all age groups, but the risk of developing atrial fibrillation (AF) increases significantly with age. As per the American Heart Association’s statistics, the prevalence rate of AF in people younger than 65 years of age is approximately 2%, while the rate increases to about 9% in people aged more than 65 years. Furthermore, the use of alcohol, tobacco, a sedentary lifestyle and certain over-the-counter drugs could also increase the risk of arrhythmias.

Other factors that are driving the market growth include a favorable reimbursement scenario and technological advancements in the field of pacemakers and minimally invasive surgeries.

Cyber security risks associated with new-generation connected pacemakers could impede market growth. In case of pacemakers that represent high-risk class medical devices, cyber security risks pose significant danger to patient safety.In the recent past, the US FDA had identified Abbott implantable products to be susceptible to cybersecurity risks, following which Abbott had initiated two voluntary recalls, in Aug 2017 and Apr 2018. These cybersecurity risks and recalls could unnecessarily alarm patients, and may have a long term negative effect on the growth of the marketKey Developments in the MarketMedtronic received FDA’s expanded indication for SelectSecure(TM) MRI SureScan(TM) pacing lead for bundle site stimulation.Companies ProfiledAbbott Inc. (St. Jude Medical)Medtronic PLCBoston Scientific CorporationSorin GroupLepu medical Co. Ltd.Zoll medical corporationBiotronik SE & Co. KGMedico SpA

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Market Dynamics

7. Market Segmentation

8. Key Players and Competitive Landscape

9. Future of the Market

For more information about this report visit https://www.researchandmarkets.com/research/2rbxds/cardiac?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180926005390/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Devices

KEYWORD:

INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/26/2018 06:24 AM/DISC: 09/26/2018 06:24 AM

http://www.businesswire.com/news/home/20180926005390/en

AP RADIO
Update hourly